Angarano G, Monno L, Appice A.
et al. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts
Yerly S, Vora S, Rizzardi P.
et al. Acute HIV infection: impact on the spread of HIV and transmission of
drug resistance. AIDS.2001;15:2287-2292.
Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants
associated with zidovudine resistance. J Infect Dis.1994;169:411-415.
Hecht FM, Grant RM, Petropoulos CJ.
et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase
and protease inhibitors. N Engl J Med.1998;339:307-311.
Ippolito G, Del Poggio P, Arici C.
et al. Transmission of zidovudine-resistant HIV during a bloody fight [letter]. JAMA.1994;272:433-434.
Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine
and zidovudine: Sydney Primary HIV Infection Study Group. J Infect Dis.1997;175:1502-1506.
Veenstra J, Schuurman R, Cornelissen M.
et al. Transmission of zidovudine-resistant human immunodeficiency virus type
1 variants following deliberate injection of blood from a patient with AIDS:
characteristics and natural history of the virus. Clin Infect Dis.1995;21:556-560.
Boden D, Hurley A, Zhang L.
et al. HIV-1 drug resistance in newly infected individuals. JAMA.1999;282:1135-1141.
Little SJ, Daar ES, D'Aquila RT.
et al. Reduced antiretroviral drug susceptibility among patients with primary
HIV infection. JAMA.1999;282:1142-1149.
Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet.1999;354:729-733.
Deeks S, Hecht F, Swanson M.
et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in
an urban AIDS clinic: response to both initial and salvage therapy. AIDS.1999;13:F35-F43.
Roland ME, Martin JN, Grant RM.
et al. Postexposure prophylaxis for human immunodeficiency virus infection
after sexual or injection drug use exposure: identification and characterization
of the source of exposure. J Infect Dis.2001;184:1608-1612.
Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease
inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis.2000;181:946-953.
Ledergerber B, Egger M, Opravil M.
et al. for the Swiss HIV Cohort Study. Clinical progression and virological failure on highly active antiretroviral
therapy in HIV-1 patients: a prospective cohort study. Lancet.1999;353:863-868.
Janssen RS, Satten GA, Stramer SL.
et al. New testing strategy to detect early HIV-1 infection for use in incidence
estimates and for clinical and prevention purposes. JAMA.1998;280:42-48.
D'Aquila RT, Schapiro J, Brun-Vezinet F.
et al. Update on drug resistance mutations in HIV-1. HIV Med.2001;9:31-33.
Yerly S, Rakik A, De Loes SK.
et al. Switch to unusual amino acids at codon 215 of the human immunodeficiency
virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant
variants. J Virol.1998;72:3520-3523.
Winters MA, Schapiro JM, Lawrence J, Merigan TC. Human immunodeficiency virus type 1 protease genotypes and in vitro
protease inhibitor susceptibilities of isolates from individuals who were
switched to other protease inhibitors after long-term saquinavir treatment. J Virol.1998;72:5303-5306.
Petropoulos CJ, Parkin NT, Limoli KL.
et al. A novel phenotypic drug susceptibility assay for human immunodeficiency
virus type 1. Antimicrob Agents Chemother.2000;44:920-928.
Lanier ER, Hellmann NS, Scott J.
et al. Determination of a clinically relevant phenotypic resistance "cutoff"
for Abacavir using the PhenoSense assay (abstract 254). Paper presented at: 8th Conference on Retroviruses and Opportunistic
Infections; February 5-6, 2001; Chicago, Ill.
Kempf D, Brun S, Rode R.
et al. Identification of clinically relevant phenotypic and genotypic break-points
for AbT-378/R in multiple PI-experienced, NNRTI-naive patients (abstract 89). Paper presented at: 4th International Workshop on HIV Drug Resistance
and Treatment Strategies, June 28-July 1, 2000; Sitges, Spain.
Haubrich R, Keiser P, Kemper C.
et al. CCTG 575: a randomized, prospective study of phenotype testing versus
standard of care for patients failing antiretroviral therapy (abstract 80). Paper presented at: 5th International Workshop on HIV Drug Resistance
and Treatment Strategies; June 4-8, 2001; Scottsdale, Ariz.
Harrigan PR, Montaner JSG, Wegner SA.
et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated
individuals: biologically relevant values for resistance testing. AIDS.2001;15:1671-1677.
Bacheler L, Ploughman L, Hertogs K, Larder B. Impact of baseline nnRTI resistance on the efficacy of efavirenz combination
therapy in nnRTI therapy-naive patients (study DMP 266-006). Paper presented at: 4th International Workshop on HIV Drug Resistance
and Treatment Strategies; June 28-July 1, 2000; Sitges, Spain.
Harrigan PR, Verbiest W, Larder B.
et al. Impact of moderate decreases in baseline nnRTI susceptibility on response
to antiretroviral therapy (abstract 86). Paper presented at: 4th International Workshop on HIV Drug Resistance
and Treatment Strategies; June 28-July 1, 2000; Sitges, Spain.
McFarland W, Kellogg T, Nieri G.
et al. San Francisco HIV Epidemiology Report: Data Available
to 1998. San Francisco, Calif: San Francisco Department of Public Health;
Staszewski S, Morales-Ramirez J, Tashima KT.
et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir,
and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection
in adults. N Engl J Med.1999;341:1865-1873.
Porter K, Pillay D, Cane P.
et al. Analysis of prevalence of HIV-1 drug resistance in primary infections
in the United Kingdom. BMJ.2001;322:1087-1088.
Deeks SG, Wrin T, Liegler T.
et al. Virologic and immunologic consequences of discontinuing combination
antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med.2001;344:472-480.
Quinn TC, Wawer MJ, Sewankambo N.
et al. Viral load and heterosexual transmission of human immunodeficiency
virus type 1: Rakai Project Study Group. N Engl J Med.2000;342:921-929.
Hirsch M, Steigbigel R, Staszewski S.
et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine
in adults with advanced human immunodeficiency virus type 1 infection and
prior antiretroviral therapy. J Infect Dis.1999;180:659-665.
Saag MS, Emini EA, Laskin OL.
et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor
of HIV-1 reverse transcriptase: L-697,661 Working Group. N Engl J Med.1993;329:1065-1072.
Montaner JS, Reiss P, Cooper D.
et al. A randomized, double-blind trial comparing combinations of nevirapine,
didanosine, and zidovudine for HIV-infected patients: the INCAS Trial: Italy,
the Netherlands, Canada and Australia Study. JAMA.1998;279:930-937.
Goudsmit J, Jan Weverling G, van der Hoek L.
et al. Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy
on transmission of resistant strains. AIDS.2001;15:2293-2301.
Hirsch M, Brun-Veninet F, D'Aquila RT.
et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations
of an International AIDS Society-USA panel. JAMA.2000;283:2417-2426.
Fauci AS, Bartlett JG, Goosby EP, Kates J. Guidelines for the use of antiretroviral agents in HIV-1 infected adults
and adolescents [HIV/AIDS Treatment Information Service Web site]. Available at: http://www.hivatis.org/trtgdlns.html. Accessed
January 7, 2002.
Miller V, Vandamme AM, Loveday C.
et al. Clinical and laboratory guidelines for the use of HIV-1 drug resistance
testing as part of treatment management: recommendations for the European
Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency
virus type 1: phenotypic analysis of protease and gag coevolution in protease
inhibitor-treated patients. J Virol.1998;72:7632-7637.
Stoddart CA, Liegler TJ, Mammano F.
et al. Impaired replication of protease inhibitor-resistant HIV-1 in human
thymus. Nat Med.2001;7:712-718.
Deeks SG, Hoh R, Grant RM.
et al. CD4(+) T cell kinetics and activation in human immunodeficiency virus-infected
patients who remain viremic despite long-term treatment with protease inhibitor-based
therapy. J Infect Dis.2002;185:315-323.
Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue
combination therapy despite detectable plasma viremia. AIDS.2002;16:201-207.
Boden D, Hurley A, Zhang L.
et al. Prevalence of HIV-1 drug resistance muations in 80 newly infected individuals
[abstract]. Antivir Ther.1999;4(suppl 1):85.
Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science.2000;287:650-654.
Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med.2001;7:1016-1020.